Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents

Toyoaki Hida, Ken ichi Kozaki, Hidemi Ito, Osamu Miyaishi, Yoshio Tatematsu, Takeshi Suzuki, Keitaro Matsuo, Takahiko Sugiura, Makoto Ogawa, Toshitada Takahashi, Takashi Takahashi

Research output: Contribution to journalArticlepeer-review

105 Citations (Scopus)

Abstract

This study reports that a selective COX-2 inhibitor JTE-522 inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC50s of various anticancer agents in vitro were reduced by up to 70%, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55%, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.

Original languageEnglish
Pages (from-to)2443-2447
Number of pages5
JournalClinical Cancer Research
Volume8
Issue number7
Publication statusPublished - Jul 22 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents'. Together they form a unique fingerprint.

Cite this